Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an update.
China Resources Pharmaceutical Group has begun a process to sell about 17.87% of its equity stake in Hefei Tianmai Biotechnology Development through a public tender on the Shanghai United Assets and Equity Exchange, with a minimum listing price of roughly RMB1.42 billion. The stake is held via its wholly owned unit China Resources Pharmaceutical Investment and its subsidiary, which together currently own less than 30% of Tianmai Biotechnology.
The sale is not yet assured, as no transferee has been identified and no binding transaction agreements have been signed, leaving completion contingent on a successful tender and agreement execution. If the process results in a deal, the disposal could reshape the group’s biotech investment portfolio and free up capital, while any transaction will be subject to Hong Kong listing rule requirements and close attention from shareholders and potential investors.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate operating through multiple subsidiaries across China. The group focuses on investment, development and distribution in the healthcare and biotech sectors, positioning itself as a major player in the mainland pharmaceutical and biotechnology markets.
YTD Price Performance: 2.47%
Average Trading Volume: 12,419,178
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.65B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.